Javascript must be enabled to use this form.

View Profile	Home Browse Faculty Facility Research Consortia Training Grants Courses Search Support About rSp Help and FAQ's Contact Us	GCC Home
Faculty Profile Last Modified Time: 10:14:19 AM Mon, 6 Apr 2020   Contact Information Paul Cinciripini Associated Profiles  Professor, Behavioral Science, Director, Tobacco Treatment Program, UT MD Anderson Cancer Center     pcinciri@mdanderson.org     713-745-1868    Web Link    Lab Webpage    Smoking Cessation, Smoking, Nicotine, Tobacco Products, Tobacco Use Disorder, Cues, Withholding Treatment, Depression, African Americans, Therapeutics, Tobacco Use Cessation, Mindfulness, Bupropion, Tobacco, Placebos, Neoplasms    Associated Profiles Research and Expertise Affiliations Appointments  Research and Expertise Research Interests   Paul M. Cinciripini, Ph.D. is Professor and Chair of the Department of Behavioral Science and Director of the Tobacco Treatment Program at the University of Texas MD Anderson Cancer Center. He has over 30 years of experience conducting basic and clinical research in the area of smoking cessation and nicotine psychopharmacology. Dr. Cinciripini has been the recipient of several NIH-, extramural- and industry-sponsored research grants and is the author of over 190 articles and book chapters. Dr. Cinciripini's major research includes studies of nicotine titration and compensation, psychophysiological effects of nicotine during stress, individual differences in the effects of nicotine on EEG and cardiovascular activity, genetic factors treatment outcome, pharmacogenetic effects of antidepressants during smoking cessation, and recent studies using startle probe and EEG/ERP methodology to examine the relations between genetics, emotional reactivity, nicotine exposure and nicotine withdrawal. He has also studied the effects of depression, coping behavior, and self-efficacy as well as genetic factors related to nicotine dependence and tested novel behavioral and pharmacological approaches for treatment. Examples of his work in this latter area include: the development of a "scheduled smoking" procedure and a recent application of this technology for delivery on a handheld computer; development of a smoking cessation video series for pregnant smokers; evaluating combination therapies using nicotine replacement, behavioral counseling, and other approaches; and testing novel pharmacological compounds, including anxiolytics, antidepressants, nicotine partial agonists, and cannabinoid antagonists. He is presently the PI on several NIH-funded clinical trials, including, "Evaluating New Nicotine Standards for Cigarettes (CENIC)," which addresses the best approach to reducing nicotine in cigarettes by comparing a gradual vs. immediate reduction to low levels of nicotine; and "Pharmacogenetics of Nicotine Addiction Treatment (PNAT)," which optimizes pharmacotherapeutic choices for individuals who wish to quit smoking.  Publications/Creative Works Click here to search for this faculty member's publications on PubMed.  Affiliations  Research Consortia GCC Cluster for Alcohol and Addiction Research  Appointments Title Department / School Institution Professor Behavioral Science MD Anderson Cancer Center

powering - The Partnership
Important Disclaimer: The responsibility for the accuracy of the information contained on these pages lies with the authors and user providing such information.